Performance of SGM-101 for the Delineation of Primary and Recurrent Tumor and Metastases in Patients Undergoing Surgery for Colorectal Cancer
A phase 3 trial testing SGM-101 in colorectal cancer, now recruiting.
Overview
Performance of SGM-101 for the Delineation of Primary and Recurrent Tumour and Metastases in Patients Undergoing Surgery for Colorectal Cancer is a phase 3 interventional study registered as NCT03659448, led by Surgimab, and recruiting when checked on 2026-09-11. Official title: Multicenter, Open-label, Randomised, Controlled, Parallel Arms Clinical Study on Performance of SGM-101, a Fluorochrome-labeled Anti-CEA Monoclonal Antibody, for Delineation of Primary/Recurrent Tumour and Metastases in Patients Undergoing Surgery for Colorectal Cancer. Planned enrolment is 300 participants (estimated). The study started in 2019-06-17 and primary completion is expected in 2024-11. No results have been posted on ClinicalTrials.gov.
Similar pages
not linked directly; found by shared links- TrialSymbiotic-GI-03: A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Chemotherapy in Adult Participants With Metastatic Colorectal Cancer
Shares Colorectal cancer and the tag ctgov-ingest.
- TrialA Study of Precemtabart Tocentecan With or Without Bevacizumab Compared to Trifluridine/Tipiracil Plus Bevacizumab in Participants With Previously Treated Metastatic Colorectal Cancer (PROCEADE-CRC-03)
Shares Colorectal cancer and the tag ctgov-ingest.
- TrialA Clinical Study of Calderasib (MK-1084) With Targeted Therapy and Chemotherapy in People With Colorectal Cancer (MK-1084-012/KANDLELIT-012)
Shares Colorectal cancer and the tag ctgov-ingest.
- TrialA Study Assessing Adverse Events and Disease Activity of Intravenously (IV) Infused Telisotuzumab Adizutecan in Adult Participants With c-Met Protein Above Cutoff Level Above Refractory Metastatic Colorectal Cancer
Shares Colorectal cancer and the tag ctgov-ingest.
- TrialA Study to Access Intravenous (IV) Telisotuzumab Adizutecan in Combination With IV Bevacizumab Compared to Standard of Care IV Bevacizumabin Combination With Oral Trifluridine and Tipiracil in Adult Participants With Refractory Metastatic Colorectal Cancer
Shares Colorectal cancer and the tag ctgov-ingest.
- TrialA Study of Neoadjuvant QL1706 in Participants With Untreated dMMR/MSI-H Resectable Colon Cancer
Shares Colorectal cancer and the tag ctgov-ingest.
- TrialA Phase II/III Study of HR070803 in Combination With Oxaliplatin, 5-fluorouracil, Calcium Folinate and Bevacizumab Versus FOLFOX in Combination With Bevacizumab for First-line Treatment of Advanced Colorectal Cancer
Shares Colorectal cancer and the tag ctgov-ingest.
- TrialA Study to Evaluate the Efficacy and Safety of Standard-of-Care Chemotherapy and Bevacizumab With or Without INCA33890 in the First-Line Treatment of Metastatic Microsatellite Stable Colorectal Cancer
Shares Colorectal cancer and the tag ctgov-ingest.